APhA announces 25 companies participating in Project Impact: Diabetes
WASHINGTON — The American Pharmacists Association Foundation announced Monday the selection of 25 companies, community health departments and other organizations — collectively known as “communities” — that will take part in the foundation’s initiative to improve care for people disproportionately affected by diabetes across the United States.
Project Impact: Diabetes is a three-year project that will integrate pharmacists into the healthcare team to address some of the challenges that people living with diabetes face. The Bristol-Myers Squibb Foundation’s Together on Diabetes initiative will provide $625,000 in funding, as well as knowledge, tools and implementation resources.
Each community selected has created an interdisciplinary model that integrates pharmacists into diabetes care. These include Price Chopper Pharmacy in Schenectady, N.Y.; Kroger Pharmacy’s Cincinnati-Dayton division; the University of Kentucky School of Pharmacy; Fink’s Pharmacy in Essex, Md.; the Appalachian College of Pharmacy in Oakwood, Va.; and others.
Report: State Medicaid programs can reap savings with increase in generic drug use
WASHINGTON — Ten states could reap significant savings by increasing the use of generic drugs in their state Medicaid programs, the Generic Pharmaceutical Association said Monday in response to a report by the American Enterprise Institute, a conservative think tank.
The report, “Overspending on Multi-Source Drugs in Medicaid,” by Alex Brill, identified states that overspend the most on their Medicaid programs, with California, Texas and Georgia topping the list.
The study found that some state Medicaid programs spend large amounts of money reimbursing pharmacies for branded drugs when cheaper generics are available. California, for example, overspent by $102 million in 2009, while Texas overspent by $31 million and Georgia by $25 million. Other states cited were Ohio, New York, Pennsylvania, Iowa, Illinois, Florida and North Carolina.
Another study, conducted earlier this year, found that the states and the federal government could save $682 million each year by increasing the Medicaid generic drug dispensing rate by 1%.
Pfizer recalls two drugs
PEAPACK, N.J. — The generics division of drug maker Pfizer is recalling supplies of two drugs due to possible mislabeling.
Greenstone announced Saturday that it would voluntarily recall 100-count bottles of citalopram 10-mg tablets and 90-count bottles of finasteride 5-mg tablets with the lot number FI0510058-A on the label. The company said a third-party manufacturer may have placed incorrect labels on the bottles. No other lots are affected.
Citalopram is used to treat depression, while finasteride is used to treat benign prostatic hyperplasia.